



General description

INN	Atezolizumab
ATC codes	L01XC18 L01FF05
Medicine type	Biological agent
EML status history	Application rejected in 2019 (TRS 1021) for Other specified malignant neoplasms of bronchus or lung Added in 2025 (TRS 1064) for Other specified malignant neoplasms of bronchus or lung Application rejected in 2025 (TRS 1064) for Adenocarcinoma of stomach Application rejected in 2025 (TRS 1064) for Hepatocellular carcinoma of liver
Therapeutic equivalent for	pembrolizumab for Other specified malignant neoplasms of bronchus or lung pembrolizumab for Adenocarcinoma of stomach
Wikipedia	Atezolizumab 
DrugBank	Atezolizumab 

Recommendations

Section Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Hepatocellular carcinoma of liver

